Global Menopause Drug Market, By Stages Type (Perimenopause, Menopause, Postmenopause), Treatment Type (Non-Hormonal Treatment, Hormonal Treatment, Herbal Supplements), Product Type (Patch, Pill, Gel, Injectable, Cream, Others), Route of Administration Types (Oral, Injectable, Topical), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Menopause Drug Market
Menopause drug market size is projected to grow at a compound annual growth rate of 4.7% over the forecast period of 2022 to 2029. Data Bridge Market Research report on menopause drug market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Menopause is basically a physiological procedure when women stop producing estrogen hormones and their menstrual periods generally come a pause. It might occur naturally and can even be acquired due to a surgery or chemotherapy. The women with menopause may experience hot flushes, tiredness, low mood, low concentration and memory troubles.
The increase in the vulnerable aging population of menopause women and increase in the demand of novel therapies across the globe is expected to accelerate the market growth in the forecast period of 2022 to 2029. Furthermore, the rise in the strategic collaboration and licensing deal between the companies will further carve the way for the growth of the market. The rise in the demand from emerging economies and increase in the technological advancements and modernization in the healthcare sector are also expected to boost the overall growth of the market within the above mentioned forecast period. However, the inadequate knowledge about menopause in some developing countries is projected to restraint the market growth rate. On the other hand, the patent expiry from many companies and introduction of generic drugs of branded version also hampers the overall growth of the market.
In addition, the rise in the research and development activities in the market are likely to create various new opportunities that will impact this menopause drug market growth in the forecast period of 2022 to 2029.The low awareness regarding this drug and the less consciousness amongst patients along with lack of advanced healthcare infrastructure is estimated to challenge the market’s growth.
This menopause drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the menopause drug market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Menopause Drug Market Scope and Market Size
Menopause drug market is segmented on the basis of stages type, treatment type, product type, administration type and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of stages type, the menopause drug market is segmented into perimenopause, menopause and postmenopause.
- On the basis of treatment type, the menopause drug market is segmented into non-hormonal treatment, hormonal treatment and herbal supplements. Non-hormonal treatment has been further segmented into paroxetine. Hormonal treatment has been further segmented into estrogen-only medicines, progestin-only medicines and combination estrogen and progestin medicines. Estrogen-only medicines have been further sub segmented into estradiol, estropipate and estropipate. Progestin-only medicines have been further sub segmented into micronized progesterone and medroxyprogesterone acetate. Combination estrogen and progestin medicines have been further sub segmented into estradiol and norethindrone acetate, estradiol and drospirenone, estradiol and levonorgestrel and others. Herbal supplements have been further segmented into ginseng and ashwagandha.
- On the basis of product type, the menopause drug market is segmented into patch, pill, gel, injectable, cream and others.
- On the basis of administration type, the menopause drug market is segmented into oral, injectable and topical.
- The menopause drug market is also segmented on the basis of end-users into hospitals, homecare, specialty clinics and others.
Menopause Drug Market Country Level Analysis
Menopause drug market is analyzed and market size information is provided by stages type, treatment type, product type, administration type and end-users as referenced above.
The countries covered in the menopause drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America leads the menopause drug market due to the high prevalence of an unhealthy lifestyle, and rising introduction of novel drugs in this region. Asia-Pacific region, on the other hand is expected to expand at a significant growth rate because of the increase in the vulnerable aging population of menopause women and increase in the demand of novel therapies.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Menopause drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Menopause Drug Market Share Analysis
Menopause drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to menopause drug market.
Some of the major players operating in the menopause drug market report are Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Cipla Inc, Allergan, Pfizer, Inc, Novo Nordisk A/S, Novartis AG, Merck & Co., Inc, Emcure, Viramal, EuroPharma USA, Boehringer Ingelheim International GmbH, Pantarhei Bioscience, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Solvay, SHIONOGI & Co., Ltd, BioSyent Inc., Glenmark Pharmaceuticals Limited and Aché Laboratórios Farmacêuticos S.A., among others.
SKU-